



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## METHODS FOR EMBOLIZING BLOOD VESSELS

### BACKGROUND OF THE INVENTION

#### Field of the Invention

This invention is directed to methods for embolizing blood vessels which methods are particularly suited for treating vascular lesions. In these methods, a non-particulate agent such as a metal coil is introduced into a  
5 vascular site (e.g., an aneurysm cavity) in conjunction with an embolizing composition comprising a biocompatible polymer and a biocompatible solvent.

The biocompatible solvent is miscible or soluble in blood and also solubilizes the polymer during delivery. The biocompatible polymer is  
10 selected to be soluble in the biocompatible solvent but insoluble in blood. Upon contact with the blood, the biocompatible solvent dissipates from the embolic composition whereupon the biocompatible polymer precipitates. Precipitation of the polymer in the presence of the non-particulate agent permits the agent to act as a structural lattice for the growing polymer  
15 precipitate.

#### References

The following publications are cited in this application as superscript numbers:

- 1  
20 Castaneda-Zuniga, et al., *Interventional Radiology*, in *Vascular Embolotherapy*, Part 1, 1:9-32, Williams & Wilkins, Publishers (1992)
- 2  
25 Hopkins, et al., "Endovascular Treatment of Aneurysms and Cerebral Vasospasms", in "Current Management of Cerebral Aneurysms", Am. Assoc. Neuro. Surgeons, A. Awad, Editor, Chapter II, pp. 219-242 (1993).
- 3  
Pruvo, et al., "Endovascular Treatment of 16 Intracranial Aneurysms with Microcoils", *Neuroradiology*, 33(suppl):S144 (Abstract) (1991).
- 4  
Mandai, et al., "Direct Thrombosis of Aneurysms with Cellulose Acetate Polymer", *J. Neurosurg.*, 77:497-500 (1992)

- 2 -

- 5 Kinugasa, et al., "Direct Thrombosis of Aneurysms with Cellulose Acetate Polymer", *J. Neurosurg.*, 77:501-507 (1992)
- 6 Casarett and Doull's *Toxicology*, Amdur et al., Editors, Pergamon Press, New York, pp. 661-664 (1975)
- 5 7 Greff, et al., *U.S. Patent Application Serial No. 08/507,863* for "Novel Compositions for Use in Embolizing Blood Vessels", filed July 27, 1995
- 8 Greff, et al., *U.S. Patent Application Serial No. 08/508,248* for "Cellulose Diacetate Compositions for Use in Embolizing Blood Vessels", filed July 27, 1995
- 10 9 Kinugasa, et al., "Early Treatment of Subarachnoid Hemorrhage After Preventing Rerupture of an Aneurysm", *J. Neurosurg.*, 83:34-41 (1995)
- 10 10 Kinugasa, et al., "Prophylactic Thrombosis to Prevent New Bleeding and to Delay Aneurysm Surgery", *Neurosurg.*, 36:661 (1995)
- 15 11 Taki, et al., "Selection and Combination of Various Endovascular Techniques in the Treatment of Giant Aneurysms", *J. Neurosurg.*, 77:37-42 (1992)
- 20 12 German, et al., *New England Journal of Medicine*, 250:104-106 (1954)
- 13 13 Rabinowitz, et al., *U.S. Patent No. 3,527,224*, for "Method of Surgically Bonding Tissue Together", issued 9/8/70
- 14 14 Hawkins, et al., *U.S. Patent No. 3,591,676*, for "Surgical Adhesive Compositions", issued 7/6/71
- 25

All of the above references are herein incorporated by reference in their entirety to the same extent as if each individual reference was specifically and individually indicated to be incorporated herein by reference in its entirety.

State of the Art

Embolization of blood vessels is conducted for a variety of purposes including the treatment of tumors, the treatment of lesions such as aneurysms, arteriovenous malformations (AVM), arteriovenous fistula (AVF), uncontrolled bleeding and the like.

Embolization of blood vessels is preferably accomplished via catheter techniques which permit the selective placement of the catheter at the vascular site to be embolized. In this regard, recent advancements in catheter technology as well as in angiography now permit neuro endovascular intervention including the treatment of otherwise inoperable lesions. Specifically, development of microcatheters and guide wires capable of providing access to vessels as small as 1 mm in diameter allows for the endovascular treatment of many lesions.

Endovascular treatment regimens include the use of non-particulate agents such as metal coils which are designed to induce thrombosis after delivery to the vascular site.<sup>1</sup> Ideally, after placement of the microcoils at the vascular site, thrombosis results in the formation of a clot about the coil thereby sealing the vascular site.

Complications in this procedure have, however, been reported including the fact that thrombosis about the metal coil is not uniform in nature and fragmentation of the resulting clot can occur. This former aspect can lead to incomplete sealing of, for example, vascular lesions, whereas the latter aspect can lead to migration of the blood clots in the patient's circulation.

Additionally, while platinum has been the metal of choice for use in metal coils, the thrombogenic potential of platinum coils is variable<sup>2</sup> and can result in incomplete sealing of the blood vessel (e.g., aneurysm). Likewise, when employed in treating aneurysms, coils are prone to migration in and/or from the aneurysm cavity after placement<sup>2</sup>. Coil migration away from the aneurysm cavity in such cases has been reported to result in regressive complete motor paralysis in treated patients.<sup>3</sup>

- 4 -

Likewise, migration within the aneurysm cavity prior to thrombosis can liberate calcified emboli from within the aneurysm cavity and cause intimal tears and vessel wall dissections.<sup>2</sup>

5 Still further, in the embolization of blood vessels, the choice of coil size is critical because the use of microcoils which are too small can result in coil migration within the patient's circulation and the use of coils which are too large for the blood vessel to be embolized can result in coil elongation which is recognized to be less efficient for blood vessel embolization.<sup>1</sup>

10 While efforts have been made to improve the thrombogenic properties of platinum coils by the incorporation of Dacron® threads onto the coils, coil migration remains a serious concern primarily due to potential severe adverse affects arising from such migration. Moreover, since thrombosis around the coils is essential for successful treatment of the  
15 aneurysm, care must be taken to minimize any breakage of clot fragments from the formed clot and incorporation of these fragments into the patient's circulation.

Still further, in treatment of lesions, it is common to employ multiple coils to effect thrombosis. However, the positioning and placement  
20 of multiple coils is technically challenging and often results in undesired coil migration, misplacement and/or altered shape of the coil pack.

In view of the above, there is an ongoing need to enhance the efficacy of blood vessel embolization using non-particulate agents such as metal coils.

25 This invention is directed to the discovery that the efficacy of blood vessel embolization via catheter delivery of microcoils and other non-particulate agents to the blood vessel site to be embolized can be enhanced by further delivering a polymer composition as described below to this site. The deposited coils or other non-particulate agents act as a lattice about  
30 which a polymer precipitate grows thereby embolizing the blood vessel.

- 5 -

While the use of polymer compositions to embolize blood vessels has heretofore been disclosed including compositions wherein a preformed polymer precipitates *in situ* from a carrier solution at the vascular site to be embolized,<sup>4,5</sup> such compositions invariably have been employed by themselves in the absence of non-particulate agents such as metal coils. For effective treatment, such polymer compositions must form a precipitate in the blood vessel having sufficient structural integrity to inhibit fragmentation of the precipitate and the precipitate must be anchored at the site of placement. While certain polymer compositions form precipitates having the requisite structural integrity<sup>7,8</sup>, other polymer compositions do not. In either case, anchoring of these precipitates to the vascular site remains a serious problem particularly in lesions having high blood flow and/or diffuse necks. In such cases, precipitate anchoring to the vascular site is not an intrinsic function of the shape of the lesion to be treated and migration of the precipitate away from the intended vascular site can occur.

In view of the above, there is an ongoing need for enhancing the efficacy of polymer compositions used for embolizing vascular sites.

### SUMMARY OF THE INVENTION

This invention is directed to the discovery that unexpected and surprising results are achieved when blood vessels are embolized with a combination of a non-particulate agent and a polymer composition in the manner described herein. In particular, deficiencies associated with each of these embolizing procedures when used separately are either reduced or eliminated by using these procedures in combination. Such deficiencies addressed by this invention include, for example, (a) problems associated with variable thrombosis about the non-particulate agent at the vascular site, (b) problems associated with non-particulate agent migration after delivery to the vascular site, (c) problems associated with polymer precipitate fragmentation after precipitate formation at the vascular site, and (d) problems associated with polymer precipitate anchoring at the vascular site.

- 6 -

Accordingly, in one of its method aspects, this invention is directed to a method for embolizing a vascular site in a patient's blood vessel which method comprises

5 (a) introducing, via a catheter, at the vascular site to be embolized a non-particulate agent or a plurality of said agents; and

(b) delivering, via a catheter, to said vascular site a polymer composition comprising a biocompatible polymer, a biocompatible solvent and a water insoluble contrast agent

10 wherein said delivery is conducted under conditions wherein a polymer precipitate forms *in situ* at said vascular site thereby embolizing the blood vessel and further wherein said non-particulate agent is encapsulated within said precipitate.

15 In the polymer composition, the biocompatible solvent is preferably dimethyl sulfoxide and the biocompatible polymer is preferably an ethylene vinyl alcohol copolymer or a cellulose acetate polymer.

20 In another embodiment, the biocompatible polymer composition can be replaced with a biocompatible prepolymer composition containing a biocompatible prepolymer. In this embodiment, this invention is directed to a method for embolizing a vascular site in a patient's blood vessel which method comprises

(a) introducing, via a catheter, at the vascular site to be embolized a non-particulate agent or a plurality of said agents; and

25 (b) delivering, via a catheter, to said vascular site a prepolymer composition comprising a biocompatible prepolymer and a water insoluble contrast agent

wherein said delivery is conducted under conditions wherein said prepolymer polymerizes *in situ* at said vascular site thereby embolizing the blood vessel and further wherein said non-particulate agent is encapsulated within said polymer.

- 7 -

In one optional embodiment, the prepolymer composition further comprises a biocompatible solvent which is preferably selected from the group consisting of dimethylsulfoxide, ethanol, and acetone.

5 In one of its kit aspects, this invention is directed to a kit of parts comprising:

(a) a polymer composition comprising a biocompatible polymer, a biocompatible solvent and a water insoluble contrast agent; and

(b) a non-particulate agent or plurality of such agents.

10 In another of its kit aspects, this invention is directed to a kit of parts comprising:

(a) a prepolymer composition comprising a biocompatible prepolymer and a water insoluble contrast agent; and

(b) a non-particulate agent or plurality of such agents.

15 Preferably, the kit further comprises a catheter capable of delivering said polymer composition.

In one embodiment, the catheter capable of delivering said polymer composition is the same as the catheter capable of delivering said non-particulate agent. In another embodiment, the catheter capable of delivering said polymer composition is different from the catheter capable of  
20 delivering said non-particulate agent. In this latter embodiment, the kit further comprises a catheter capable of delivering said non-particulate agent.

In another embodiment, the kit further comprises a microballoon catheter to attenuate blood flow.

### **DETAILED DESCRIPTION OF THE INVENTION**

25 This invention is directed to methods for embolizing vascular sites which methods incorporate both a non-particulate agent and a polymer or prepolymer composition at the vascular site to be embolized.

However, prior to discussing this invention in further detail, the following terms will first be defined:

- 8 -

The term "embolizing" refers to a process wherein a material is injected into a blood vessel which, in the case of for example aneurysms, fills or plugs the aneurysm sac and/or encourages clot formation so that blood flow into the aneurysm ceases, and in the case of AVM's and AVF's forms a plug or clot to control/reroute blood flow to permit proper tissue perfusion. Embolization of the blood vessel is, therefore, important in preventing/controlling bleeding due to lesions (e.g., organ bleeding, gastrointestinal bleeding, vascular bleeding as well as bleeding associated with an aneurysm). In addition, embolization can be used to ablate diseased tissue (e.g., tumors, etc.) by cutting off its blood supply.

The term "non-particulate agent" refers to biocompatible macroscopic solid materials having a discrete physical shape or structure which, when placed in a blood vessel, result in embolization of the blood vessel. The non-particulate agents are macroscopic (i.e., about 1 mm or larger in size) which is contrasted with particulates which are microscopic (i.e., less than 1 mm in size). Examples of such non-particulate agents include, coils (including metallic coils, coils with barbs, etc.), silk streamers, plastic brushes, detachable balloons (e.g., silicon or latex balloons), foam (e.g., polyvinyl alcohol foam), nylon mesh and the like. Such non-particulate agents are generally commercially available. For example, platinum coils are available from Target Therapeutics, San Jose, California, USA.

The specific non-particulate agent employed is not critical and preferred agents include metallic coils, metallic coils with barbs, metallic coils with fibers (e.g., Dacron® wool fibers) and/or streamers, etc. More preferably, platinum coils are employed.

The term "biocompatible polymer" refers to polymers which, in the amounts employed, are non-toxic, chemically inert, and substantially non-immunogenic when used internally in the patient and which are substantially insoluble in blood. Suitable biocompatible polymers include, by way of example, cellulose acetates<sup>5,9-10</sup> (including cellulose diacetate<sup>8</sup>),

- 9 -

ethylene vinyl alcohol copolymers<sup>7,11</sup>, polycarbonate urethane copolymers, hydrogels (e.g., acrylics), polyacrylonitrile and the like. Preferably, the biocompatible polymer is also non-inflammatory when employed *in situ*.

5 The particular biocompatible polymer employed is not critical and is selected relative to the viscosity of the resulting polymer solution, the solubility of the biocompatible polymer in the biocompatible solvent, the compatibility of the polymer composition with the non-particulate agent and the like. Such factors are well within the skill of the art.

10 Preferred biocompatible polymers include cellulose diacetate and ethylene vinyl alcohol copolymer. Cellulose diacetate polymers are either commercially available or can be prepared by art recognized procedures. In a preferred embodiment, the number average molecular weight, as determined by gel permeation chromatography, of the cellulose diacetate composition is from about 25,000 to about 100,000 more preferably from  
15 about 50,000 to about 75,000 and still more preferably from about 58,000 to 64,000. The weight average molecular weight of the cellulose diacetate composition, as determined by gel permeation chromatography, is preferably from about 50,000 to 200,000 and more preferably from about 100,000 to about 180,000. As is apparent to one skilled in the art, with all other  
20 factors being equal, cellulose diacetate polymers having a lower molecular weight will impart a lower viscosity to the composition as compared to higher molecular weight polymers. Accordingly, adjustment of the viscosity of the composition can be readily achieved by mere adjustment of the molecular weight of the polymer composition.

25 Ethylene vinyl alcohol copolymers comprise residues of both ethylene and vinyl alcohol monomers. Small amounts (e.g., less than 5 mole percent) of additional monomers can be included in the polymer structure or grafted thereon provided such additional monomers do not alter the embolizing properties of the composition. Such additional monomers  
30 include, by way of example only, maleic anhydride, styrene, propylene, acrylic acid, vinyl acetate and the like.

- 10 -

Ethylene vinyl alcohol copolymers are either commercially available or can be prepared by art recognized procedures. Preferably, the ethylene vinyl alcohol copolymer composition is selected such that a solution of 6 weight percent of the ethylene vinyl alcohol copolymer, 35 weight percent of a tantalum water insoluble contrast agent in DMSO has a viscosity equal to or less than 60 centipoise at 20°C. As is apparent to one skilled in the art, with all other factors being equal, copolymers having a lower molecular weight will impart a lower viscosity to the composition as compared to higher molecular weight copolymers. Accordingly, adjustment of the viscosity of the composition as necessary for catheter delivery can be readily achieved by mere adjustment of the molecular weight of the copolymer composition.

As is also apparent, the ratio of ethylene to vinyl alcohol in the copolymer affects the overall hydrophobicity/hydrophilicity of the composition which, in turn, affects the relative water solubility/insolubility of the composition as well as the rate of precipitation of the copolymer in an aqueous solution (e.g., blood). In a particularly preferred embodiment, the copolymers employed herein comprise a mole percent of ethylene of from about 25 to about 60 and a mole percent of vinyl alcohol of from about 40 to about 75. These compositions provide for requisite precipitation rates suitable for use in embolizing blood vessels.

The term "contrast agent" refers to a radiopaque material capable of being monitored during injection into a mammalian subject by, for example, radiography. The contrast agent is typically water insoluble (i.e., has a water solubility of less than 0.01 mg/ml at 20°C). Examples of water insoluble contrast agents include tantalum, tantalum oxide and barium sulfate, each of which is commercially available in the proper form for *in vivo* use including a particle size of about 10  $\mu\text{m}$  or less. Other water insoluble contrast agents include gold, tungsten and platinum.

The term "biocompatible solvent" refers to an organic material liquid at least at body temperature of the mammal in which the biocompatible

- 11 -

polymer is soluble and, in the amounts used, is substantially non-toxic. Suitable biocompatible solvents include, by way of example, dimethylsulfoxide, analogues/homologues of dimethylsulfoxide, ethanol, acetone, and the like. Aqueous mixtures with the biocompatible solvent can also be employed provided that the amount of water employed is sufficiently small that the dissolved polymer precipitates upon contact with the blood. Preferably, the biocompatible solvent is dimethylsulfoxide.

The term "encapsulation" as used relative to the water insoluble contrast agent and/or non-particulate agent being encapsulated in the polymer precipitate is not meant to infer any physical entrapment of the water insoluble contrast agent within the precipitate much as a capsule encapsulates a medicament. Rather, this term is used to mean that an integral coherent precipitate forms which does not separate into individual components.

The term "biocompatible prepolymer" refers to materials which polymerize *in situ* to form a polymer and which, in the amounts employed, are non-toxic, chemically inert, and substantially non-immunogenic when used internally in the patient and which are substantially insoluble in blood. Suitable biocompatible prepolymers include, by way of example, cyanoacrylates<sup>1,13,14</sup>, hydroxyethyl methacrylate, silicon prepolymers, urethane prepolymers, and the like. The prepolymer can either be a monomer or a reactive oligomer<sup>13</sup>. Preferably, the biocompatible prepolymer is also non-inflammatory when employed *in situ*.

### Compositions

The polymer or prepolymer compositions employed in the methods of this invention are prepared by conventional methods whereby each of the components is added and the resulting composition mixed together until the overall composition is substantially homogeneous.

For example, polymer compositions can be prepared by adding sufficient amounts of the biocompatible polymer to the biocompatible

- 12 -

solvent to achieve the effective concentration for the polymer composition. Preferably, the polymer composition will comprise from about 2.5 to about 8.0 weight percent of the biocompatible polymer composition based on the total weight of the polymer composition and more preferably from about 4  
5 to about 5.2 weight percent. If necessary, gentle heating and stirring can be used to effect dissolution of the biocompatible polymer into the biocompatible solvent, e.g., 12 hours at 50°C.

Sufficient amounts of the water insoluble contrast agent are then added to the solution to achieve the effective concentration for the complete  
10 polymer composition. Preferably, the polymer composition will comprise from about 10 to about 40 weight percent of the water insoluble contrast agent and more preferably from about 20 to about 40 weight percent and even more preferably 35 weight percent based on the total weight of the composition. Because the contrast agent is not soluble in the biocompatible  
15 solvent, stirring is employed to effect homogeneity of the resulting suspension. In order to enhance formation of the suspension, the particle size of the contrast agent is preferably maintained at about 10  $\mu\text{m}$  or less and more preferably at from about 1 to about 5  $\mu\text{m}$  (e.g., an average size of about 2  $\mu\text{m}$ ).

20 In one preferred embodiment, the appropriate particle size of the water insoluble contrast agent is prepared, for example, by fractionation. In such an embodiment, a water insoluble contrast agent such as tantalum having an average particle size of less than about 20 microns is added to an organic liquid such as ethanol (absolute) preferably in a clean environment.  
25 Agitation of the resulting suspension followed by settling for approximately 40 seconds permits the larger particles to settle faster. Removal of the upper portion of the organic liquid followed by separation of the liquid from the particles results in a reduction of the particle size which is confirmed under an optical microscope. The process is optionally repeated  
30 until a desired average particle size is reached.

- 13 -

The particular order of addition of components to the biocompatible solvent is not critical and stirring of the resulting suspension is conducted as necessary to achieve homogeneity of the composition. Preferably, mixing/stirring of the composition is conducted under an anhydrous atmosphere at ambient pressure. The resulting composition is heat sterilized and then stored preferably in sealed bottles or vials (e.g., amber vials) until needed.

Prepolymer compositions can be prepared by adding sufficient amounts of the water insoluble contrast agent to the solution to achieve the effective concentration for the complete polymer composition. Preferably, the prepolymer composition will comprise from about 10 to about 40 weight percent of the contrast agent and more preferably from about 20 to about 40 weight percent and even more preferably 35 weight percent. Again, because the contrast agent is not soluble in the biocompatible prepolymer composition, stirring is employed to effect homogeneity of the resulting suspension. In order to enhance formation of the suspension, the particle size of the water insoluble contrast agent is preferably maintained at about 10  $\mu\text{m}$  or less and more preferably at from about 1 to about 5  $\mu\text{m}$  (e.g., an average size of about 2  $\mu\text{m}$ ).

When the prepolymer is liquid (as in the case of polyurethanes), the use of a biocompatible solvent is not absolutely necessary but may be preferred to provide for an appropriate viscosity, etc. in the embolic composition. Preferably, when employed, the biocompatible solvent will comprise from about 50 to about 90 weight percent of the biocompatible prepolymer composition based on the total weight of the prepolymer composition and more preferably from about 60 to about 80 weight percent.

In a particularly preferred embodiment, the prepolymer is cyanoacrylate which is preferably employed in the absence of a biocompatible solvent. When so employed, the cyanoacrylate adhesive is selected to have a viscosity of from about 5 to about 20 centipoise at 20°C.

The particular order of addition of components is not critical and

- 14 -

stirring of the resulting suspension is conducted as necessary to achieve  
homogeneity of the composition. Preferably, mixing/stirring of the  
composition is conducted under an anhydrous atmosphere at ambient  
pressure. The resulting composition is sterilized and then stored preferably  
5 in sealed amber bottles or vials until needed.

### Methods

The compositions described above are then employed in methods for  
embolizing mammalian blood vessels. In these methods, the non-particulate  
agent (e.g., platinum coils) is first introduced to the vascular site to be  
10 embolized via conventional catheter technology. See, for example, Hopkins  
et al.<sup>2</sup> for a discussion of conventional catheter techniques for introduction  
of such agents into the vascular site.

After introduction of the non-particulate agent to the vascular site, a  
sufficient amount of the polymer composition is introduced by conventional  
15 means (e.g., catheter delivery under fluoroscopy). Upon discharge of the  
polymer composition from the catheter into the vascular site, the bio-  
compatible solvent dissipates into the blood resulting in precipitation of the  
biocompatible polymer. The precipitate forms around the non-particulate  
agent which acts as a lattice for precipitate growth and eventual blood  
20 vessel embolization. In turn, the non-particulate agent anchors the growing  
precipitate to the vascular site and is selected relative to its ability to remain  
at the vascular site.

The particular amount of polymer composition employed is dictated  
by the total volume of the vasculature to be embolized, the concentration of  
25 polymer in the composition, the rate of precipitation (solids formation) of  
the polymer, the size and number of non-particulate agents employed, etc.  
Such factors are well within the skill of the art. For example, the rate of  
precipitation can be controlled by changing the overall hydrophobicity/hy-  
drophilicity of the polymer with faster precipitation rates being achieved by  
30 a more hydrophobic polymer composition.

- 15 -

The particular combination of non-particulate agent and polymer composition employed is governed by the compatibility of these materials with each other. Each component is deemed compatible if it is essentially inert in the presence of the other components. For example, when dimethyl sulfoxide is employed as the biocompatible solvent in the polymer composition, the non-particulate agent is selected to be compatible with this solvent. Accordingly, plastic, wool and wood coils would typically not be employed in combination with such a polymer composition insofar as such coils may degrade in the presence of dimethyl sulfoxide. Contrarily, platinum coils are essentially inert in the presence of dimethyl sulfoxide and, accordingly, such a combination would be compatible.

One particularly preferred method for delivering the non-particulate agent and the polymer composition to the selected vascular site is via a small diameter medical catheter. The particular catheter employed is not critical provided that polymeric catheter components are compatible with the polymeric composition (i.e., the catheter components will not readily degrade in the polymer composition and none of the components of the polymer compositions will readily degrade in the presence of the catheter components). In this regard, it is preferred to use polyethylene in the catheter components because of its inertness in the presence of the polymeric composition described herein. Other materials compatible with the embolizing compositions can be readily determined by the skilled artisan and include, for example, other polyolefins, fluoropolymers (e.g., Teflon<sup>TM</sup>), silicone, etc.

When delivered by catheter, the injection rate of the polymer composition dictates, in part, the form of the precipitate at the vascular site. Specifically, low injection rates of approximately 0.05 to 0.3 cc/minute will provide for a precipitate in the form of a kernel or nodule which is particularly beneficial for site specific embolization (e.g., aneurysms) because the precipitate forms primarily at the point of injection. Contrarily, high injection rates of about 0.1 to 0.5 or more cc/several seconds (e.g., up

- 16 -

to 10 seconds) will provide for a filament like mass projecting downstream from the catheter tip which is particularly beneficial for providing the embolizing agent deep into the vascular tree. Such procedures are suitable for embolizing tumor masses and organs.

5           When introduced into the vascular site, the non-particulate agent may become fixed against the vascular wall thereby anchoring the embolic site. Addition of the polymer composition to this site results in rapid diffusion of the biocompatible solvent into the blood and a solid precipitate forms which precipitate is the biocompatible polymer/contrast agent with  
10           the non-particulate agent encapsulated therein. Without being limited to any theory, it is believed that initially, a soft gel to spongy solid precipitate forms upon contact with the blood and non-particulate agent which precipitate is open and fibrous in structure and forms around the non-particulate agent. This precipitate then restricts blood flow, entrapping red  
15           cells thereby causing clot embolization of the blood vessel.

          Without being limited to any theory, the methods of this invention address the prior art problems recited above because problems associated with variable thrombosis about the non-particulate agent at the vascular site are reduced because this agent is encapsulated in the polymer precipitate  
20           and further because this agent is not the only thrombic agent employed to effect embolization but rather is employed in conjunction with the polymer precipitate. Also, encapsulation of the non-particulate agent in the polymer composition minimizes migration of these agents. Additionally, since the non-particulate agent acts as a structural lattice, the structural integrity of  
25           the precipitate is enhanced thereby minimizing fragmentation. Lastly, because the non-particulate agent acts as an appropriate anchor, the precipitate is held in position more effectively than if only the polymer composition was employed to embolize the blood vessel.

          The methods described herein can also employ a biocompatible  
30           prepolymer such as cyanoacrylate in place of or in conjunction with the polymer composition described above. When the prepolymer is liquid (as

- 17 -

in the case of cyanoacrylates), the use of a biocompatible solvent is not absolutely necessary but may be preferred to provide for an appropriate viscosity, etc. in the embolic composition. Upon injection into the vascular site, the prepolymer will polymerize *in situ* upon contact with the blood and form a solid polymer around the non-particulate agent thereby encapsulating this agent in the polymer and embolizing the blood vessel.

For polymer compositions, the methods of this invention are conveniently practiced by use of a kit of parts comprising:

- (a) a polymer composition comprising a biocompatible polymer, a biocompatible solvent and a water insoluble contrast agent; and
- (b) a non-particulate agent or plurality of such agents.

For prepolymer compositions, the methods of this invention are conveniently practiced by use of a kit of parts comprising:

- (a) a prepolymer composition comprising a biocompatible prepolymer and a water insoluble contrast agent; and
- (b) a non-particulate agent or plurality of such agents.

Preferably, in either case, the kit further comprises a catheter capable of delivering said polymer or prepolymer composition.

In one embodiment, the catheter capable of delivering said polymer or prepolymer composition is the same as the catheter capable of delivering said non-particulate agent. In another embodiment, the catheter capable of delivering said polymer or prepolymer composition is different from the catheter capable of delivering said non-particulate agent. In this latter embodiment, the kit further comprises a catheter capable of delivering said non-particulate agent.

In another embodiment, the kit further comprises a microballoon catheter to attenuate blood flow.

### Utility

The methods described herein are useful in embolizing mammalian blood vessels which, in turn, can be used to prevent/control bleeding due to

- 18 -

lesions (e.g., organ bleeding, gastrointestinal bleeding, vascular bleeding, bleeding associated with an aneurysm) or to ablate diseased tissue (e.g., tumors, etc.). Accordingly, these methods find use in human and other mammalian subjects requiring embolization of blood vessels.

5           The kit of parts described herein find particular utility for use with these methods because the kit conveniently provides all of the components required to practice the described methods.

          It is contemplated that the methods described herein can also be employed non-vascularly, for example, in fallopian tubes or the vas deferens  
10       to effect female and male sterilization respectively or delivered as a bulking material to the periurethral tissue of a mammal for treating incontinence.

          The following examples are set forth to illustrate the claimed invention and are not to be construed as a limitation thereof.

#### EXAMPLES

15           Unless otherwise stated, all temperatures are in degrees Celsius. Also, in these examples and elsewhere, the following abbreviations have the following meanings:

	cc	=	cubic centimeter
	DMSO	=	dimethylsulfoxide
20	EVOH	=	ethylene vinyl alcohol copolymer
	mm	=	millimeter
	μm	=	micron

          In the following examples, Examples 1-2 illustrate the preparation of polymer compositions useful in the methods described herein which  
25       polymer compositions comprise cellulose acetate and EVOH. Example 3 illustrates how such polymer compositions could be used in the methods of this invention.

- 19 -

#### EXAMPLE 1

A cellulose diacetate polymer composition was prepared by dissolving cellulose acetate (39.7 weight percent acetyl content) into DMSO to provide for an 6.8 weight percent concentration of the copolymer in  
5 DMSO. To this solution was added tantalum (10 weight percent, available from Leico Industries, New York, New York, USA, 99.95% purity, less than 43  $\mu\text{m}$  in size).

In the tantalum composition, tantalum settling can result from prolonged standing. Sonification may help but thorough mixing prior to use  
10 is required.

#### EXAMPLE 2

An EVOH polymer composition was prepared by dissolving EVOH (44 mole percent ethylene) into DMSO to provide for an 6.8 weight percent concentration of the copolymer in DMSO. In order to facilitate dissolution,  
15 the system can be heated to 50°C overnight.

To this solution was added tantalum (10 weight percent, available from Leico Industries, New York, New York, USA, 99.95% purity, less than 43  $\mu\text{m}$  in size or from H.C. Starck, Inc. (Newton, Massachusetts, USA) having a particle size of about 5  $\mu\text{m}$ ) as a water insoluble contrast agent.

In the tantalum composition, tantalum settling can result from prolonged standing. Sonification may help but thorough mixing prior to use  
20 is required.

Tantalum having a particle size of 10  $\mu\text{m}$  or less, can be used and is either commercially available (e.g., H.C. Starck, supra) or can be made as  
25 follows. Specifically, tantalum having a particle size of about 3  $\mu\text{m}$  (narrow size distribution) was prepared by fractionation wherein tantalum, having an average particle size of less than about 20  $\mu\text{m}$ , was added to ethanol (absolute) in a clean environment. Agitation of the resulting suspension was followed by settling for approximately 40 sec. to permit the  
30 larger particles to settle faster. Removal of the upper portion of the ethanol

- 20 -

followed by separation of the liquid from the particles results in a reduction of the particle size which is confirmed under a microscope (Nikon Alphaphot<sup>TM</sup>). The process was repeated, as necessary, until an average 3  $\mu\text{m}$  particle size was reached.

5

### EXAMPLE 3

The purpose of this example is to illustrate an *in vivo* application of the methods of this invention in the treatment of an aneurysm.

Specifically, a rabbit was prepared with bilateral femoral access. Into the first femoral access was placed a microcatheter (non-sterile, non-coated, with two distal bands 2 cm apart) which had the tip shaped into a "J" using heat. It was placed over a 0.014 inch (0.0355 cm) Dasher guidewire and into the aneurysm. After sizing the aneurysm, a 5 mm x 10 cm GDC-10 coil (available from Target Therapeutics, San Jose, CA) was placed into the aneurysm through the microcatheter and then detached electrolytically over approximately 2½ minutes. The periphery and center portion of the aneurysm remained open.

A second microcatheter was placed through the second access site and the tip positioned into the center of the aneurysm. The first microcatheter was pulled back just proximal to the aneurysm to reduce blood flow and allow contrast injection for visualization. The rabbit was turned to place the aneurysm in the dependent position. The volume of the aneurysm was calculated to be about 0.045 cc.

The embolic composition of Example 2 (particle size of less than 10  $\mu\text{m}$ ) above was shaken for about 4 minutes until the contrast agent was fully dispersed. Microcatheter placement was confirmed by injection of water soluble contrast agent (e.g., Omnipaque<sup>TM</sup> available from Nycomed, Princeton, New Jersey). After placement, a syringe containing saline was connected to the luer hub of the microcatheter and the water soluble contrast agent was flushed from the microcatheter hub and body with about 5 cc of saline over an approximately 1 minute period with gentle pulsing at

- 21 -

1 cc increments. Afterwards, the syringe was removed and a cap was secured on the microcatheter luer hub.

Sterile DMSO (0.5 cc) was aspirated into a 1 cc syringe. The cap was removed from the microcatheter hub and the syringe fitted thereto.

5 About 0.30 cc of DMSO was injected into the catheter to remove the saline therefrom.

While the DMSO was being prepared and injected, the embolic composition was shaken for about 2 minutes to fully disperse the water insoluble contrast agent. A 1 cc syringe was then filled with the embolic composition using a 21 gage needle. As soon as the DMSO has been  
10 injected, the syringe was removed and the balance of the DMSO used for overfilling and washing the luer hub.

Afterwards, the syringe containing the embolic composition was immediately connected to the catheter hub, making sure that there was no  
15 air in the hub during the connection. With the composition syringe pointing up to create a sharp interfacial boundary between the DMSO and the embolic composition, the first 0.25 cc was injected over a 1 minute period to displace the DMSO in the microcatheter and dilute the DMSO in the blood. Under fluoroscopy, the embolic composition was visible in the distal  
20 portion of the microcatheter body. The syringe tip was lowered and the embolic composition then injected. The volume of the embolic composition was monitored to ensure that the amount of embolic composition injected corresponded to the volume of the vascular space being filled. Upon completion of the embolic composition injection, the embolic syringe was  
25 gently aspirated to separate the catheter tip from the embolic composition mass. After a few seconds, the syringe plunger was released and the microcatheter withdrawn.

A total of 0.07 cc of embolic composition was delivered into the aneurysm. Immediate post injection angiography revealed a filled aneurysm  
30 and an open parent (carotid) artery. Another angiogram taken approximately 2 minutes later showed that a portion of the Embolyx had

- 22 -

migrated from the aneurysm into the parent artery and caused partial occlusion.

It is understood that the same procedures set forth above can be employed with compositions employing liquid prepolymers. However, when so employed, the timing and injection rates will vary depending on the cure rate for the prepolymer. Such factors are within the skill of the art.

From the foregoing description, various modifications and changes in the composition and method will occur to those skilled in the art. All such modifications coming within the scope of the appended claims are intended to be included therein.

**WHAT IS CLAIMED IS:**

1. A method for embolizing a vascular site in a patient's blood vessel which method comprises

5 (a) introducing, via a catheter, at the vascular site to be embolized a non-particulate agent or a plurality of said agents; and

(b) delivering, via a catheter, to said vascular site a polymer composition comprising a biocompatible polymer, a biocompatible solvent and a water insoluble contrast agent having an average particle size of about 10  $\mu\text{m}$  or less;

10 wherein said delivery is conducted under conditions wherein a polymer precipitate forms *in situ* at said vascular site thereby embolizing the blood vessel and further wherein said non-particulate agent is encapsulated within said precipitate.

2. A method for embolizing an aneurysm in a mammalian patient which method comprises

15 (a) introducing, via a catheter, into the aneurysm cavity a metallic coil or a plurality of metallic coils;

(b) delivering, via a catheter, to said cavity a polymer composition comprising a biocompatible polymer, dimethyl sulfoxide and a water 20 insoluble contrast agent selected from the group consisting of tantalum, tantalum oxide, tungsten and barium sulfate wherein the water insoluble contrast agent has an average particle size of about 10  $\mu\text{m}$  or less;

25 wherein said delivery is conducted under conditions wherein a polymer precipitate forms *in situ* in the aneurysm cavity thereby blocking the aneurysm and further wherein said metallic coil is encapsulated within said precipitate.

- 24 -

3. The method according to Claim 1 wherein said biocompatible solvent is selected from the group consisting of dimethylsulfoxide, ethanol, and acetone.

5 4. The method according to Claim 3 wherein said biocompatible solvent is DMSO.

5. The method according to Claim 1 wherein said water insoluble contrast agent is selected from the group consisting of tantalum, tantalum oxide, tungsten and barium sulfate.

10 6. The method according to Claim 1 wherein said non-particulate agent is a metallic coil or a plurality of metallic coils.

7. The method according to Claims 2 or 5 wherein said metallic coil is a platinum coil.

8. The method according to Claim 1 or 2 wherein said contrast agent is tantalum.

15 9. The method according to Claims 1 or 2 wherein the polymer composition is injected into the aneurysm at a rate of about 0.05 to 0.3 cc/minute.

10. The method according to Claims 1 or 2 wherein the polymer composition is injected into the aneurysm at a rate of at least 0.6 cc/minute.

20 11. A kit of parts comprising:

(a) a polymer composition comprising a biocompatible polymer, a biocompatible solvent and a water insoluble contrast agent; and

(b) a non-particulate agent or plurality of such agents.

- 25 -

12. A kit of parts comprising:
  - (a) a prepolymer composition comprising a biocompatible prepolymer and a water insoluble contrast agent; and
  - (b) a non-particulate agent or plurality of such agents.
- 5           13. The kit of parts according to Claim 12 wherein said kit further comprises a biocompatible solvent.
14. The kit of parts according to Claims 11 or 13 wherein said biocompatible solvent is selected from the group consisting of dimethylsulfoxide, ethanol, and acetone.
- 10           15. The kit of parts according to Claim 14 wherein said biocompatible solvent is DMSO.
16. The kit of parts according to Claims 11 or 12 wherein said water insoluble contrast agent is selected from the group consisting of tantalum, tantalum oxide, tungsten and barium sulfate.
- 15           17. The kit of parts according to Claims 11 or 12 wherein said non-particulate agent is a metallic coil or a plurality of metallic coils.
18. The kit of parts according to Claim 17 wherein said metallic coil is a platinum coil.
19. The kit of parts according to Claims 11 or 12 wherein the kit  
20 further comprises a catheter capable of delivering said polymer composition.

- 26 -

20. The kit of parts according to Claim 19 wherein the catheter capable of delivering said polymer composition is also capable of delivering said non-particulate agent.

5 21. The kit of parts according to Claim 19 which further comprises a catheter capable of delivering said non-particulate agent.

22. A method for embolizing a vascular site in a patient's blood vessel which method comprises

(a) introducing, via a catheter, at the vascular site to be embolized a non-particulate agent or a plurality of said agents; and

10 (b) delivering, via a catheter, to said vascular site a prepolymer composition comprising a biocompatible prepolymer and a contrast agent wherein said delivery is conducted under conditions wherein said prepolymer polymerizes *in situ* at said vascular site thereby embolizing the blood vessel and further wherein said non-particulate agent is encapsulated  
15 within said polymer.

23. The method according to Claim 22 wherein said prepolymer composition further comprises a biocompatible solvent.

20 24. The method according to Claim 23 wherein said biocompatible solvent is selected from the group consisting of dimethylsulfoxide, ethanol, and acetone.

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/01076

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC(6) :A61M 1/00  
 US CL :604/49  
 According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**  
 Minimum documentation searched (classification system followed by classification symbols)  
 U.S. : 604/49

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
 NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
 APS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 3,527,224 A (RABINOWITZ) 08 September 1970, entire document.	1-24
Y	US 3,591,676 A (HAWKINS et al) 06 July 1971, entire document.	1-24

Further documents are listed in the continuation of Box C.  See patent family annex.

* Special categories of cited documents:	*T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A document defining the general state of the art which is not considered to be of particular relevance	*X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E earlier document published on or after the international filing date	*Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z document member of the same patent family
*O document referring to an oral disclosure, use, exhibition or other means	
*P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 21 MAY 1997	Date of mailing of the international search report 05 JUN 1997
--	---

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer <i>Manuel Antonio Mendez</i> MANUEL ANTONIO MENDEZ Telephone No. (703) 308-2221
---	---